The Marcu Lab is developing FLIm as a non-destructive method to monitor engineered biomaterials. Growing and manipulating biomaterials to be used as tissue substitutes requires close monitoring of the tissue biochemical, structural and functional properties. Most tools and methods to measure the samples’ properties are destructive in nature, which render the tissue unusable after examination. As a result, a lot of samples are required to elaborate protocols and methods, which demands many resources and has an elevated cost.
FLIm relies on the autofluorescence lifetime of cells and tissue components to provide information on biochemical and structural changes. Fluorescence lifetime is highly sensitive to the fluorophore microenvironment, which changes with different maturation stages of the engineered biomaterials. In addition, the label-free and non-destructive nature of the approach allows for in vivo imaging of the tissue in the host after implantation, providing a means to monitor the healing process and to predict possible failure events.
Our previous work has focused on vascular, cartilage, and bone tissue engineering. We have demonstrated the ability of FLIm to monitor scaffold structural properties such as the cross-linking and digestion of collagen networks, the recellularization of natural vascular scaffolds, and FLIm’s ability to detect the maturation stages of osteogenic grafts.
The tissue engineering work is also a platform for technology development including multimodal imaging, see FLIm-OCT, FLIm-Raman, endo-exo platform.
Collaborators
Leigh G. Griffiths, Ph.D. (Mayo Clinic)
Prof. J. Kent Leach (UC Davis)
Kyriacos A. Athanasiou, Ph.D, Ph.M. (UC Davis/UC Irvine)
Funding
NIH (National Institutes of Health): R01HL121068
CIRM (California Institute for Regenerative Medicine): RT3-07879, RT3-07981